Clinigen predicts full-year profits boost
Profits at Burton-based Clinigen are expected to rise by 22% for the year-ending 30 June, the firm said this morning (18 July).
The profits hike will be driven by a combination of organic growth across all operations, a full year’s contribution from Link Healthcare and currency benefits, says Clinigen.
Shaun Chilton, group chief executive officer of Clinigen Group said: “This has been another excellent year with all three operations, CTS, Unlicensed Medicines and Commercial Medicines, performing strongly.
“We have made significant progress in our strategy to build scale and capability in high growth geographies in Africa and Asia Pacific. Now that Link’s earn-out period has been completed, we will be able to further integrate and develop our complementary portfolio of businesses worldwide.
“Our priorities in the current financial year remain unchanged. We will drive organic growth across all parts of the Group and search for selective acquisitions to complement our existing offering and capabilities.”
Clinigen expects to publish its final results for the year ended 30 June 2017 on Thursday 28 September.
